A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2010

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Nov 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01011959).
    • 13 Nov 2009 Actual start date (December 2008), official title, actual patient number (60), location (USA), primary outcome, lead investigator (Radin A) and sanofi-aventis added as trial sponsor as reported by ClinicalTrials.gov.
    • 21 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top